Chugai files Japan application for Tecentriq as adjuvant MSI-high colon cancer treatment
XLV•Japan application for Tecentriq in MSI-high colon cancer
Chugai filed with Japan’s health ministry for Tecentriq as adjuvant treatment for MSI-high colon cancer in adults, pediatric patients.
Application backed by Phase III ATOMIC trial in resected stage III dMMR colon cancer using Tecentriq with mFOLFOX6.
Three-year DFS reached 86.3% with Tecentriq regimen, 76.2% with mFOLFOX6; hazard ratio 0.50; p<0.001.
